Description
Anti-IL1 beta antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
Applications
"On-target" tumor antigen binding
Technology
ATP-mediated antibody engineering technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL1 beta antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Interleukin 1 Beta
Background
Canakinumab;914613-48-2;ACZ885;DB06168Catabolin;H1;Hematopoietin 1;IFN beta inducing factor;IL 1;IL 1 beta;IL 1B;IL-1 beta;IL1 BETA;IL1F2;Interleukin 1 beta;Interleukin 1 beta precursor;Interleukin-1 beta;LAF;OAF;Osteoclast activating factor;OTTHUM
Antibody Clone
AES-0622-ZP915
Description
Anti-IL1 beta antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
